TABLE 2.
Baseline characteristics of the 32 subjects who started study drugsa
| Characteristic | Regimen A (n = 16) | Regimen B (n = 16) |
|---|---|---|
| Gender (no. of subjects) | ||
| Male | 14 | 15 |
| Female | 2 | 1 |
| Race (no. of subjects) | ||
| White | 9 | 15 |
| Black | 4 | 1 |
| Other | 3 | 0 |
| HIV risk factors (no. of subjects) | ||
| Male homosexual or bisexual contact(s) | 12 | 12 |
| Male homosexual or bisexual contact(s) and intravenous drug use | 2 | 1 |
| Heterosexual contact or sex with intravenous drug user | 1 | 2 |
| Unknown | 1 | 1 |
| Mean (SD) age (yr) | 36.3 (8.0) | 36.8 (7.8) |
| Mean (SD) wt (kg) | 68.7 (10.3) | 74.3 (8.2) |
| Mean (SD) body surface area (m2) | 1.8 (0.2) | 1.9 (0.1) |
| Mean (SD) CD4 cell count (cells/mm3) | 67 (50) | 82 (52) |
a
Regimen A, clarithromycin on days 1 to 14 and both study drugs on days 15 to 42; regimen B, rifabutin on days 1 to 14 and both study drugs on days 15 to 42.